Pasar al contenido principal

IMPLICACION DE LA DISBIOSIS ORAL MEDIADA POR LA INFECCION POR PORPHYROMONAS GINGIVALIS EN LA ENFERMEDAD DE ALZHEIMER Y APROXIMACION TERAPEUTICA CON LACTOFERRINA

PID2022-139195OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Salivary lactoferrin levels in Down Syndrome: a case-control study.

  • Antequera, Desireé
  • Sande, Lucía
  • Mato, Eliane García
  • Romualdi, Deborah
  • Carrero-Olivas, Laura
  • Municio-Rueda, Cristina
  • Diz, Pedro
  • Carro, Eva
Individuals with Down Syndrome (DS) have a high age-dependent risk of developing Alzheimer's disease (AD). In addition to genetic causes, this high risk involves dysregulated immune-inflammatory system. Low lactoferrin levels, one of the main antimicrobial proteins present in saliva, has been associated with AD. Here, we evaluated whether salivary lactoferrin levels change across the life span of individuals with DS. The study included 152 participants, 72 subjects with DS and 80 euploid individuals, and were divided into those under and over 45 years of age, accordingly with the age-dependent risk of AD. Median of salivary lactoferrin were higher among DS individual, in parallel to salivary total protein, but there were no differences in the ratio of lactoferrin to total protein in saliva between groups. Only DS individuals had higher median salivary lactoferrin levels in the age group under 45 years. Meanwhile non-significant differences were detected for the ratio salivary lactoferrin levels to total salivary protein between groups under 45 years, those levels were lower in DS subjects over 45 years old compared with the age-matched control group. Furthermore, the ratio of salivary lactoferrin levels to total protein in DS was associated with cognitive decline being lower in demented groups compared with mild and moderate cognitive impairment groups. In summary, this study indicates that salivary lactoferrin was dysregulated in DS, with significant lower ratio of salivary lactoferrin levels to total salivary proteins in individuals with DS over 45 years old, a population with a gradually increasing risk of AD.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Salivary lactoferrin levels in Down Syndrome: a case-control study

  • Antequera, Desireé
  • Sande López, Lucía
  • García Mato, Eliane
  • Romualdi, Deborah
  • Carrero, Laura
  • Municio, Cristina
  • Diz Dios, Pedro
  • Carro, Eva
Individuals with Down Syndrome (DS) have a high age-dependent risk of developing Alzheimer's disease (AD). In addition to genetic causes, this high risk involves dysregulated immune-inflammatory system. Low lactoferrin levels, one of the main antimicrobial proteins present in saliva, has been associated with AD. Here, we evaluated whether salivary lactoferrin levels change across the life span of individuals with DS. The study included 152 participants, 72 subjects with DS and 80 euploid individuals, and were divided into those under and over 45 years of age, accordingly with the age-dependent risk of AD. Median of salivary lactoferrin were higher among DS individual, in parallel to salivary total protein, but there were no differences in the ratio of lactoferrin to total protein in saliva between groups. Only DS individuals had higher median salivary lactoferrin levels in the age group under 45 years. Meanwhile non-significant differences were detected for the ratio salivary lactoferrin levels to total salivary protein between groups under 45 years, those levels were lower in DS subjects over 45 years old compared with the age-matched control group. Furthermore, the ratio of salivary lactoferrin levels to total protein in DS was associated with cognitive decline being lower in demented groups compared with mild and moderate cognitive impairment groups. In summary, this study indicates that salivary lactoferrin was dysregulated in DS, with significant lower ratio of salivary lactoferrin levels to total salivary proteins in individuals with DS over 45 years old, a population with a gradually increasing risk of AD.